Showing results (1-10 of 68) with videos related to
Sort By:
Pageof 7
Cell Chemical Biology|January 18, 2020
Severing Ties: Quantifying the Payload Release from Antibody Drug ConjugatesAnna Kopp, Greg M ThurberFrontiers in Pharmacology|March 21, 2022
Predictive Simulations in Preclinical Oncology to Guide the Translation of BiologicsShujun Dong, Ian Nessler, Anna Kopp, et al.Molecular Cancer Therapeutics|October 3, 2022
Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug ReleaseAnna Kopp, Scott Hofsess, Thomas M Cardillo, et al.Neoplasia (New York, N.Y.)|January 6, 2024
Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agentsAnna Kopp, Hyeyoung Kwon, Colette Johnston, et al.The AAPS Journal|June 11, 2024
Design of Crosslinking Antibodies For T-Cell Activation: Experimental and Computational Analysis of PD-1/CD137 Bispecific AgentsAnna Kopp, Jiakun Guan, Colette Johnston, et al.Biorxiv : the Preprint Server for Biology|April 22, 2024
In vivo Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesAnna Kopp, Shujun Dong, Hyeyoung Kwon, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 23, 2018
Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug ConjugatesEshita Khera, Greg M ThurberMolecular Imaging and Biology|September 3, 2010
Quantitating antibody uptake in vivo: conditional dependence on antigen expression levelsGreg M Thurber, Ralph WeisslederMolecular Imaging and Biology|July 22, 2015
Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular ImagingLiang Zhang, Greg M ThurberScientific Reports|May 10, 2022
Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targetingReginald Evans, Greg M ThurberPageof 7